Welcome from the Congress President - Yasuo Ikeda -

Allow me to begin by extending my heartfelt sympathy to all those affected by the Great East Japan Earthquake. I would like to express my gratitude to all those who have exerted their best efforts to organize the XXIII Congress of the International Society on Thrombosis and Haemostasis. The discipline of thrombosis and haemostasis has been developing and prevailing to a great extent. While the Tokyo Congress in 1989 attracted some 3,000 participants, the Geneva and Boston Congresses, held four years and two years ago respectively, were attended by about 8,000 participants. I would say this increase in the number of participants proves that those from various disciplines throughout the world are paying more attention to the study of thrombosis. Therefore, “Dispatch from Asia” was selected as a key word for the main theme of this Congress. Medical studies have become fully borderless. It is an era where new drugs are being developed all over the world and are then used across borders. There remains, however, a challenge regarding ethnicity; that is, whether or not a drug developed in a region is also applicable to other regions or different population groups as it is. In this context, the study of thrombosis will draw more and more attention. Asia is no exception. Western countries still lead in medical studies, but now that national borders have become blurred, it is important to discuss global issues here in Asia and develop understandings. The Presidential Symposium will focus on four important research subjects of thrombosis and the haemostasis studies: platelet; coagulation; fibrinolysis; and vascular wall. Leading experts will review research findings and present their prospects for how the current researches will lead to future ones. The symposium will be a valuable opportunity for the participants to comprehensively understand how the study has developed from the past to the present and will develop from the present to the future. Moreover, new therapeutic strategies will be introduced substantially as the progress of new drugs for thrombosis has remarkably developed over the last few years. It is time for the researches to be reviewed at the Presidential Symposium to indicate and promote new directions. I feel honored to have the ISTH Congress here in Kyoto at this important time and expect that it will add momentum to the evolution of therapies.

It is also my hope that you can take this opportunity to fully enjoy Kyoto, where the longstanding “spirit of hospitality” among Japanese is still deeply ingrained and authentic cuisine prevails. Through your experiences in Kyoto, you may come to know about the Japanese heart and mind and the country’s history. It would be appreciated if you could share such experiences with others in your country, hopefully remarking on how attractive Japan is, as private diplomats having been impressed by Japanese culture as well as academic exchanges.

Finally, I would like to reiterate my appreciation to the Council members who unanimously agreed that the Congress should proceed as planned in Kyoto, taking into account the difficult situation after the disaster; to the Council Chairman Dr. Henri Bounameaux who sent the Members his encouraging message urging that a visit to Japan itself will prove its safety and hence will support the Japanese people; and to each of the participants of this Congress.

---

**Monday at a Glance**

**Ongoing**
- Oral Communications
- State-of-the-Art Lectures
- Symposia

**9:45 a.m. - 10:30 a.m.**
- Plenary Lecture
- Gene Therapy for Hemophilia: A Long and Winding Road (K. A. High)

**12:15 p.m. - 1:15 p.m.**
- Poster Discussion

**5:15 p.m. - 6:00 p.m.**
- Plenary Lecture
- Biological Functions and Therapeutic Potential of Vascular Endothelial Growth Factors (K. Alitalo)

**6:15 p.m. - 8:15 p.m.**
- Special Symposia

---

**Monday, July 25, 18:15 – 20:15**
Special Symposia by generous support from cooperate partners.

- Factors for Life - Advances in Treatment of Congenital and Coagulopathic Bleeding Disorders (CSL Behring, Annex Hall 2)
- Challenges and Progress in the Management of Joint Health in Haemophilia Patients (Novo Nordisk) Room A
- Burden on Anti-thrombotic Therapy – How Do You Select Anti-platelet Agents? (Otsuka) Room B-1
- Chronic Anticoagulation in AF: Optimization of Treatment (Daichi Sankyo) Room D
- Long-term Oral Anticoagulation: Debating the Future (Bayer) Sakura

---

**TIPS OF THE DAY**

**Monday, July 25, 18:15 – 20:15**

- shuttle service is available between hotels and congress center from July 25 to July 28.
- Exhibition open from 10:30a.m. to 18:00p.m.
- The Congress site has wireless internet available at no charge.

The ISTH 2011 Daily Congress news will also appear on the ISTH website at www.isth.org.
Welcome from ISTH Chairman of Council
-Interview with Henri Bounameaux

It is my distinct privilege to extend to you a warm welcome to Kyoto. For the second time in its history, our Society will be convening in Japan—twenty-two years after the Tokyo Congress, but in a very special situation due to the recent disaster in North-Eastern Japan. I very much enjoyed Tokyo 1989 and I am sure that I will enjoy Kyoto 2011 as well.

-What of the Science Are You Looking Forward To?

As a clinical scientist mainly active in the field of venous thromboembolism, I will try to attend most of the scientific sessions on related topics. But I will not miss the occasion of enriching my knowledge not only of other clinical fields but also in basic science. Indeed, I am convinced that translational projects that bring together basic and clinical scientists will represent the cornerstone of medical progress in the next decades.

-How did the natural disaster that occurred in Japan in early March impact this congress?

Clearly, the unprecedented earthquake and tsunami followed by the nuclear plant accident devastated the Fukushima region in North-Eastern Japan and had further far reaching impact on the country and indeed the world. This generated a multitude of comments and questions from overseas colleagues concerned about the safety of holding the Congress in Kyoto. The ISTH leadership worked with the Kyoto Local Organizing Committee and with an international company to assess the risk to all congress participants. Based on all available objective evidence, Council firmly concluded that holding the congress in Kyoto did not present a health or transportation safety hazard.

Reconfirming the Congress to be held in Japan was also important for the ISTH Council to reiterate our support to the Japanese people and ISTH community in their continued recovery efforts. Council recognizes also that Dr. Yasuo Ikeda and his Local Organizing Committee have made great efforts to ensure a successful, stimulating scientific meeting of the highest caliber. As a matter of fact, nobody can avoid irrational fears and the number of participants is less than anticipated but the number of abstracts is almost as high as in Boston and in Geneva, which means that the ISTH congresses are the leading events in our field and we can certainly appreciate that some participants ultimately opted not to travel to Japan.

-What Are the Chairman of Council’s Responsibilities during a Congress?

Although the Council is not directly involved in the organization of the Congress, we do a lot of business here. For instance, the Council’s Annual Meeting will be held Tuesday night, where important strategic discussions take place and decisions will be made about the ISTH, in particular about future congress venues. This congress was preceded by a whole day of meetings of all the committees of the Council that deal with, for instance, publications, education and outreach, finance, governance, membership, awards, etc. In addition, there are meetings with industry partners, with the publisher and the editorial board of the JTH, with organizers of future ISTH meetings. I will also have some official functions during the Opening Ceremony and the Presidents’ Dinner. Two new events at this Congress, which I have really enjoyed a lot, are the meeting of the Outreach Forum with young scientists from all over the world, organized by Professor Frits Rosendaal, and the awardee and trainee reception. These are great initiatives and symbolize what congresses are so important for: bringing our global community together.

-What Do You See as the Strong Points of the ISTH?

ISTH is the only scientific society that links basic researchers and clinical scientists in the fields of thromboembolic and hemorrhagic diseases as well as in vascular biology. We also have a strong journal, the Journal of Thrombosis and Haemostasis with a high reputation and Impact Factor. Our other two main strong points are our biennial congresses and yearly SSC meetings and a strong and growing education and outreach program.

-Where do you see the greatest opportunities for ISTH in the future?

We have to take advantage of ISTH’s unique position by attracting more young scientists, to foster their knowledge by organizing more educational sessions in our meetings (this already started a few years ago), by initiating e-learning (first attempt presented here in Kyoto), by supporting education in less developed parts of the world (Asia, Africa and South-America) and also in developed countries as planned in November of this year together with the European School of Hematology, in Cascais, Portugal. In order to further support these strong points, our task will be to strengthen our congress organization and ensure continuity from one event to the next in close collaboration with the Local Organizing Committee, the ISTH HQs and professional congress organizers (PCOs). This will allow us to increase the efficiency, effectiveness and progressive innovation while preserving the local flavor of each congress.

-What else are you looking forward to for the rest of the week?

I look forward to meeting many colleagues and friends from around the world and making new acquaintances and connections. I sincerely hope that my administrative duties will allow me to take part in many scientific sessions and in the great social program, thereby allowing us to show our Japanese colleagues our solidarity in this difficult period.

Henri Bounameaux, MD
Welcome to the Otuka’s booth
We are looking forward to seeing you

Exhibition Hall 1  Booth No. 26

Experience and Discovery
Exhibition Opening Hours
July,25 10:30-18:00
July,26 10:30-18:00
July,27 9:30-16:00
July,28 9:30-16:00

and then Memory
Taking a picture
July,25 11:00-12:00 14:00-15:00 16:00-17:00 (three times)
July,26 11:00-12:00 14:00-15:00 16:00-17:00 (three times)
July,27 11:00-12:00 (once)
July,28 11:00-12:00 14:00-15:00 (two times)

Date of preparation : June, 2011

Cilostazol Stroke Prevention Study

ANTIPLATELET AGENT

Pletaal® tablets 50mg
Pletaal® tablets 100mg

Japanese Pharmacopoeia: Cilostazol Tablets

See package insert (labeling) for a complete description of indications, dosage and administration, warning, contraindications, and other important medical information.

For further information, contact the Drug Information Center, Headquarters for Product Safety and Quality Assurance, Otsuka Pharmaceutical Co., Ltd., Shinagawa Grand Central Tower, 2-16-4 Konan, Minato-ku, Tokyo 108-8242, Japan

Otsuka
Otsuka-people creating new products for better health worldwide
J TH - Interview with Mike Greaves and David Lane

How has the Journal Progressed Over Time?

We inherited the Journal when Pier Mannucci stepped down as Editor in Chief. The format of the Journal is largely unchanged, although there have been adjustments to the proportions of articles in each type, with perhaps fewer Letters to the Editor now. Of course the Journal has become more established over time and now is regarded as the leading specialty journal in its area.

What are your editorial priorities?

manuscripts received, impact factor, associate editors

Our Editorial priority has been to attract the best quality original papers in thrombosis and haemostasis, to provide rigorous review of their content and to publish the accepted articles as rapidly as possible. Currently, we receive ~1400 manuscripts a year, accept less than 30% of these, with a first decision time of less than 3 weeks. We are greatly assisted in this process by our team of expert Associate Editors, who have full authority to take decisions. We watch the impact factor with some bemusement. Unlike some competitor journals, we do not overtly try to manipulate the impact factor, such as by enhancing self-citation, because our mission has been to serve science, not a metric.

Why is JTH a leading journal and why should scientists and clinicians select it as their first choice to submit their best work?

The strength of JTH is that it is the official journal of the ISTH. The members of ISTH form an expert body of readers, reviewers and commentators. Publishing in JTH immediately brings high visibility to this expert group.

What Do You Hope to Do in Your Time Remaining?

The ISTH is in the process of appointing a new Editor in Chief and a phased take over will begin in August 2012. This means that there is not much scope for major changes to the journal under our editorship. We feel that the new editor(s) should have every opportunity to make their mark on the journal.

What do you like to do in your time off, what are your hobbies or interests outside of work?

Mike Greaves: It took me until around age 16 years to understand that, although a sports enthusiast, I have no hand-eye coordination whatsoever and am therefore useless at most competitive sports. This led me to try running, which requires no special skills at all. As it is the only sporting activity in which I have any degree of competence I have persevered with it into my dotage. In my remaining spare time I grow vegetables.

David Lane: In the last few years, I have become a fan of cycling. I often cycle to and from work, which takes about 2 hours a day, but I also very much enjoy cycling around London. This City has made big improvements in infrastructure for cyclists, making it a lot safer. I enjoy viewing the many architectural styles in different parts of the City. A second interest is reading fiction. I am a member of a local book club which meets once a month: recent great reads have been The Feast of the Goat by Mario Vargas Llosa and Wolf Hall by Hilary Mantel.

The Wiley Blackwell booth (publisher of the journal),
It is located at: Exhibition Hall 1: #33
The ISTH booth also has information about the Journal.
It is located at: Main Event Hall: #5
At the booths you can find: JTH Editorial Staff, a promotional USB with JTH content and general JTH information

“Visit the Exhibition” announcement

ISTH delegates can get their first look on Monday at the ISTH Exhibition. Participants can visit booths to find out more about the latest technology, health care advances and opportunities. Commercial displays of international organizations, sponsor pharmaceutical companies, media publishers and scientific societies will be located in Event Hall and Exhibition Hall 1 & 2.

Exhibition hours
- Monday 10:30-18:00
- Tuesday 10:30-18:00
- Wednesday 09:30-14:00
- Thursday 09:30-16:00

Visit the ISTH Booth

Located in the Main Event Hall at Booth #5, the ISTH booth will assist delegates with information about the Society and its programs and activities. Easily renew your membership or sign up as a member. Here you can also speak with editorial staff from the Society’s official journal, Journal of Thrombosis and Haemostasis. Find information at the booth about other ISTH educational resources and benefits. Visit the ISTH Booth today!

Gilbert C. White II recognition

D r. Gilbert C. White II was presented with a plaque honoring his dedication and service to the Society as Executive Director. Dr. White was the Executive Director of the Society from 1999 to 2009. This recognition was presented to Dr. White at the Opening Ceremony of the Congress. The Society recognizes Dr. White’s time and talent, wise leadership, and undivided loyalty to the Society and its members. He provided the Society with scientific leadership and advised 6 Chairmen of ISTH Council, 6 Chairmen of the SSC, 6 Congress Meeting Presidents, and 4 Editors of JTH during his term as Executive Director. In addition, Dr. White was an advisor and counselor to the Chairs of the Scientific Subcommittees, and he represented the SSC to many international agencies and organizations. He took an active role in the organization of each SSC Annual Meeting and provided guidance and support to the Local Organizers. As Executive Director, he was an esteemed representative of ISTH to the international scientific community.

“Visit the Exhibition” announcement

ISTH delegates can get their first look on Monday at the ISTH Exhibition. Participants can visit booths to find out more about the latest technology, health care advances and opportunities. Commercial displays of international organizations, sponsor pharmaceutical companies, media publishers and scientific societies will be located in Event Hall and Exhibition Hall 1 & 2.

Exhibition hours
- Monday 10:30-18:00
- Tuesday 10:30-18:00
- Wednesday 09:30-14:00
- Thursday 09:30-16:00

Visit the ISTH Booth

Located in the Main Event Hall at Booth #5, the ISTH booth will assist delegates with information about the Society and its programs and activities. Easily renew your membership or sign up as a member. Here you can also speak with editorial staff from the Society’s official journal, Journal of Thrombosis and Haemostasis. Find information at the booth about other ISTH educational resources and benefits. Visit the ISTH Booth today!
# Advances in Oral Anticoagulation

**Tuesday 26 July 2011, 18:15–19:45**
Annex Hall 1

## Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:15</td>
<td>Co-Chair’s welcome and introduction</td>
<td>Ken Okumura, Japan</td>
</tr>
<tr>
<td>18:20</td>
<td>Breakthroughs in the prevention and treatment of VTE</td>
<td>Sam Schulman, Canada</td>
</tr>
<tr>
<td>18:35</td>
<td>Current challenges in stroke prevention in patients with atrial fibrillation</td>
<td>Jeffrey Weitz, Canada</td>
</tr>
<tr>
<td>18:50</td>
<td>New insights from the landmark Phase III RE-LY® trial – oral anticoagulation is evolving</td>
<td>Gregory Lip, UK</td>
</tr>
<tr>
<td>19:10</td>
<td>Introducing a novel oral anticoagulant – clinical practice implications</td>
<td>Michael Ezekowitz, USA</td>
</tr>
<tr>
<td>19:30</td>
<td>Panel discussion with questions from the floor</td>
<td>Moderated by Gregory Lip</td>
</tr>
<tr>
<td>19:40</td>
<td>Conclusions and closing remarks</td>
<td>Ken Okumura, Japan</td>
</tr>
</tbody>
</table>
The late Professor Takeshi Abe (1916-2005) was a distinguished physician-scientist who had led the Medical Society of Thrombosis and Hemostasis in Japan from the early 1960s till the late 1980s. He was one of the founders of the Japanese Society on Thrombosis and Hemostasis which started its activity in 1978, with the official journal, the Japanese Journal of Thrombosis and Hemostasis currently edited by Prof. Y Ozaki. Among his contributions were the introduction and promotion of comprehensive care of patients with hemophilia in the early 1980s, including the home treatment regimen, and establishment of the National Foundation of Japan for Comprehensive Care of Hemophiliacs. Dr. Abe served as the General Secretary of the organizing committee of the XI Congress of World Federation of Hemophilia held in Tokyo, Japan in 1976 and as the President of the XI Congress of International Society on Thrombosis and Haemostasis in 1989, which was the first ISTH Congress held in Japan. Dr. Abe was also an outstanding mentor and clinician who fostered a number of young doctors and investigators across the country, as well as his direct fellow workers, who later on established their own distinguished careers, and became major opinion leaders, and their dedication altogether has made the Japanese Society on Thrombosis and Hemostasis as it stands now.

The late Professor Takeshi Abe

The Life Sciences Research Partners is the new name of the Colleen Foundation. In 2000, Dr. Colleen established a lectureship through a contribution to the Society from the Colleen Foundation. Colleen, who is the founding director of the Molecular Cardiovascular Medicine Group in Leuven, Belgium, and chief executive officer and chairman of the board of ThromboGenics Ltd., a biopharmaceutical drug development company of Ireland, established the lectureship to further the scientific mission of the Society. Eighteen years ago, he also provided a generous donation to start what is now the Reach the World program that supports the travel of young individuals from all over the world to our meetings. Author of more than 630 papers, Colleen has research interests in the molecular biology and pathophysiology of hemostasis and thrombosis, the development of novel thrombolytic and antithrombotic agents, the pathogenesis and treatment of atherosclerosis, and gene targeting and gene transfer studies of the cardiovascular system. His team initially developed therapeutic tissue plasminogen activator (t-PA), a drug that revolutionized the treatment approach in patients with thrombotic disorders. Previous lectures endowed by the Colleen Foundation (now Life Science Research Partners) were delivered by Judah Folkman, Charles Esmon, Ryozo Nagai, Bruce Furie, and Rudolf Jaenisch.

Katherine A. High

Kari Kustaa Alitalo

Medical Prize, Norway, both in 2010. Notably, his publications have been cited over 45,000 times according to the Institute of Scientific Information (June 2011).

Today, Dr. Karl Kustaa Alitalo will deliver the Life Sciences Research Partners Lecture entitled "Biological Functions and Therapeutic Potential of Vascular Endothelial Growth Factors". In his lecture, Dr. Alitalo will highlight the importance of angiogenesis in tumor progression and knowledge of angiogenic signaling pathways, and explain the mechanism of angiogenic growth factors and lymph-angiogenic growth factors that involve inflammation and tumor dissemination; thus exploring the feasibility of future therapies.

Dr. Kari Kustaa Alitalo is a tenured Research Professor of the Finnish Academy of Sciences and Scientific Director of the Centre of Excellence in the Biomedicum Helsinki research institute of the University of Helsinki. He obtained M.D. and Ph. D. degrees from the University of Helsinki in Finland and did his postdoctoral studies with Drs. Michael Bishop and Harold Varmus. A significant achievement by Dr. Alitalo was the isolation and characterization of the first lymphangiogenic growth factor VEGF-C, its receptor VEGFR-3, and the isolation of lymphatic endothelial cells, opening up the lymphatic vascular system to molecular analysis after over a hundred years of descriptive pathology. He has also been central in the cloning and characterization of the endothelial Tie-1 receptor and the VEGF-B growth factor. He has characterized the endothelial VEGF-C and VEGF-D growth factors, their receptors, signal transduction pathways and functions, showing that VEGFR-3 is required for angiogenesis and lymphangiogenesis. Dr. Alitalo has devised molecular therapies for lymphedema that are now entering clinical trials. His studies led to the demonstration of VEGF-C induced tumor angiogenesis and lymphangiogenesis, intralymphatic tumor growth, and VEGF-C association with tumor metastasis and its inhibition by blocking the VEGFR-3 signal transduction pathway. The inhibitors of these pathways have now entered phase I clinical trials. Dr. Alitalo has received numerous prominent scientific acknowledgements and awards (most recently the Michael O’Connor Award, Mayo Clinic and the Anders Jahn Senior KT Awards).
Lixiana® TABLETS (一般名: エドキサバタン硫酸塩水和物)

Please refer to the package insert for detailed product information such as indications, dosage and administration, warnings, precautions and contraindications. (only available in Japanese)

LIXIANA is currently approved only in Japan.
Robert P. Grant Medal Presented to Désiré Collen

Désiré Collen (St Truiden, Belgium) received the 2011 Grant Medal for his outstanding research accomplishments and his dedicated service to ISTH. After Dr Collen had obtained his medical degree, he took a PhD in Chemistry, and specialized in Internal Medicine, all at the University of Leuven in Belgium. Following his specialization he spent a year in New York and a year in Stockholm, which set off his very successful scientific career. In 1981 he was appointed full Professor at the medical school in Leuven, which was a position he kept for over 25 years, leading the Center for Molecular and Vascular Biology. He founded the Collen Research Foundation and later Thrombogenics Inc., to further his research in the treatment of cardiovascular diseases. His name is of course tied to his research into the fibrinolytic system and the discovery of tPA as a fibrinolytic agent. This discovery was so enormous that sometimes his very many other scientific achievements are pushed somewhat to the background, even though he published over 800 papers during a period of over 40 years, which continue to appear in the most prominent journals. Nevertheless, the story of tPA is impressive and inspiring, for it is an example of ‘translational medicine’ (long before that phrase became popular or was even coined) where a finding in the laboratory has become standard therapy in acute arterial events and has saved numerous lives. Furthermore, it shows that serendipity does not exist, or at most has a minor role in great discoveries. In a series of publications, in Nature, Science, the Lancet and the New England Journal of Medicine the laboratory findings are presented, which already are founded on many years of hard work, followed by applications in animal models, in the exceptional patient, and finally in randomised trials of patients with myocardial infarction.

Dr Collen has inspired and mentored many now established investigators in his homeland Belgium as well as all over the world. He was the main initiator of the Flemish Institute of Biotechnology and founded the eminent Vesalius Research Center in Leuven.

Dr Collen received numerous awards for his work, amongst which four doctorates honoris causa. To this, the Grant Medal, the highest award of the ISTH, is added today. Not only to recognise Dr Collen as a leading figure in our field, but also to acknowledge his contributions to the Society, as an elected member of the SSC, as a member of Council (1990 to 1996) and as a member of the organisation committee of the 1987 Congress in Brussels.

Frits R. Rosendaal
Grant Medal Jury, Chairman

Désiré Collen Background

Désiré Collen established a lectureship in 2000 through a contribution to the Society from the Collen Foundation. The Collen Foundation has been renamed the Life Science Research Partners. Collen, who is the founding director of the Molecular Cardiovascular Medicine Group in Leuven, Belgium, and chief executive officer and chairman of the board of ThromboGenics Ltd, a biopharmaceutical drug development company of Ireland, established the lectureship to further the scientific mission of the Society. Eighteen years ago, he also provided a generous donation to start what is now the ISTH’s Reach the World program that supports the travel of young individuals from all over the world to our meetings. Author of more than 620 papers, Collen has research interests in the molecular biology and pathophysiology of hemostasis and thrombosis, the development of novel thrombolytic and antithrombotic agents, the pathogenesis and treatment of atherosclerosis, and gene targeting and gene transfer studies of the cardiovascular system. His team initially developed therapeutic tissue plasminogen activator (t-PA), a drug that revolutionized the treatment approach in patients with thrombotic disorders. Previous lectures endowed by the Collen Foundation were delivered by Judah Folkman, Charles Esmon, Ryozo Nagai, Bruce Furie, and Rudolf Jaenisch.

About Robert P. Grant

Robert P. Grant (1915–1966), for whom the award is named, was a renowned cardiologist with interdisciplinary interests. He served on the staff and ultimately became director of the National Heart Institute in Bethesda Maryland, and also served as a representative of the National Institutes of Health in Europe. He had a great interest in the development of young scientists and clinicians, and he worked to facilitate international research and communication.

About the Grant Medal

The Robert P Grant Medal is the highest award of the ISTH. It is presented at each biennial Congress of the Society to a recipient selected for outstanding service or accomplishment which has promoted the goals of the Society. This award may be for research achievement, for organizational activities, for important public recognition and support of research activities, for facilitation of institutional cooperation and communications, for unusual teaching or educational initiatives, or for the development of concepts which result in a clearer understanding of the meaning of research data.
Benefits of membership in ISTH include:

- An international network of over 3,000 members in more than 80 countries
- Priority registration and discounted fees for ISTH meetings and congresses
- Complimentary print subscription for regular members and online subscription for all membership categories to ISTH’s *Journal of Thrombosis and Haemostasis*
- Access to the ISTH members-only online resources, including educational materials, e-learning and membership directory
- Exclusive access and/or reduced fees for other educational activities, programs and publications
- The quarterly ISTH Newsletter and regular e-updates
- The right to nominate, elect and serve on ISTH committees

The International Society on Thrombosis and Haemostasis is the leading worldwide organization dedicated to the advancement of the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

ISTH provides a forum for discussion, encourages research and fosters the dissemination and exchange of ideas through scientific meetings and publications, education initiatives, research activities, expert committees and standardization of nomenclature and methods.
THROMBOSIS RESEARCH
The Official Journal of the European Thrombosis Research Organisation (ETRO) and Affiliated Journal to the North American Thrombosis Forum (NATF)

Thrombosis Research is an international journal with a goal of rapid dissemination of new information on thrombosis, hemostasis, and vascular biology to advance science and clinical care.

The journal publishes peer-reviewed original research, along with reviews, editorials, and opinions and critiques. Both basic and clinical studies are published. Publication of research which will lead to novel approaches in diagnosis, therapy, prognosis and prevention of thrombotic and hemorrhagic diseases is given high priority.

Rapid publication and high visibility is facilitated by online submission, processing, and dissemination through SciVerse ScienceDirect with powerful online links to other journals and sources.

ALSO PUBLISHED BY ELSEVIER:

Thrombosis Research is the Official Journal of European Thrombosis Research Organisation (ETRO) and members of this Society receive online access to the journal as a benefit of membership.

www.etro.eu.org

The journal is affiliated to the North American Thrombosis Forum (NATF), a discounted rate is available to members of NATF.

www.natfonline.org

More information about Thrombosis Research and how to subscribe is available at:

www.thrombosisresearch.com
Managing haemophilia for life: Treatment trends in haemophilia B

Wednesday
July 27, 2011
14:15 – 15:45
Sakura Room

Chairman:
Dr Man-Chiu Poon (Canada)

Agenda

14:15  Chairman’s welcome and introduction
       Dr Man-Chiu Poon (Canada)

14:20  The global haemophilia B landscape
       Dr Man-Chiu Poon

14:35  Current trends in Asia
       Professor Renchi Yang (China)

14:55  Global perspectives on haemophilia B treatment
       Dr Paul Monahan (USA)

15:30  Panel discussion
       Moderated by Dr Man-Chiu Poon

15:40  Chairman’s summary
       Dr Man-Chiu Poon

15:45  Close

Please also plan to visit the Pfizer Exhibit Booth #36.
Sponsors

ISTH and ISTH 2011 wish to recognize its partners and sponsors for their support in making this Congress successful:

Platinum Sponsors

Gold Sponsors

Silver Sponsors

Bronze Sponsors

Local Organizing Committee

Fumimaro Takaku
Special Adviser

Hidehiko Saito
Honorary President

Yasuo Ikeda
President

Akira Yoshioka
Vice President, SSC Chair

Koji Suzuki
Vice President, Scientific Program Committee Chair

Yukio Ozaki
Editor, “State of the Art Book”

Tetsuhide Kojima
Co-Editor, “State of the Art Book”

Mitsuru Murata
Secretary General

Nobuhiro Yamada
Supervisor

Kazuyuki Shimada
Supervisor

Osamu Matsuo
Chairman, Financial Committee

Hajime Tsuji
Co-Chairman, Financial Committee

Yoichi Sakata
Chairman, Registration Committee

Katsuyuki Fukutake
Co-Chairman, Registration Committee

Akitada Ichinose
Chairman, Promotion Committee

Morio Arai
Co-Chairman, Promotion Committee

Katsuo Sueishi
Chairman, Liaison Committee

Shinichiro Uchiyama
Co-Chairman, Liaison Committee

Hiroshi Shigematsu
Chairman, Commemoration Committee

Yutaka Yatomi
Co-Chairman, Commemoration Committee

Masao Nakagawa
Chairman, Social Program Committee

Junki Takamatsu
Co-Chairman, Social Program Committee

Masao Nakabayashi
Chairman, Award Committee

Webcasting information

Webcasts from the ISTH 2011 XXIII Congress are coming soon! The Congress Plenary Lectures, State of the Art Lectures, and the Presidential Symposium will be webcast for the post-meeting use of registered delegates and all ISTH members. The session will be available as a downloadable podcast to computers. You will be able to access the sessions via the “Members Only” section of the ISTH website. Instructions will be directly emailed to all ISTH members and registered delegates in the weeks following the Congress.

Changes & Corrections in ISTH2011 Final Program

- P-MO-007=Withdrawn
- P-MO-052=Withdrawn
- P-MO-358=Withdrawn
- P-MO-362=Withdrawn
- P-MO-468=MITRAL VALVE PROSTHESIS LEAK AND ACQUIRED VON WILLEBRAND SYNDROME (AVWS)
- P-MO-582=Withdrawn
- Oral Communications: Malignancy and Thrombosis II: Chairpersons: John-Bjarne Hansen (NO) and Janusz Rak (CA)